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MDMA (Ecstasy), a methylamphetamine derivative, has been found to produce 
severe and somewhat selective damage to CNS serotonergic (5-HT) neurons. This 
damage, though extensive, does not involve cell death. The ganglioside GM 1 has 
demonstrated potential neurotrophic properties which may enhance the rate of recovery of 
the neurons from the MDMA-induced effects. To assess this GM1 effect, MDMA (20 
mglkg x 4 days), GM1 (40 mgkg), MDMA and GM1 or saline was injected (i.p.) into 
male rats. Behavioral activity was determined for 24 hours on day 5 or day 12 following 
the beginning of the injections. A general increase in activity on day 5 was noted for the 
MDMA group (consistent with a release of 5-HT and/or catecholamines) while the activity 
of the MDMA/GM 1 group was lower, at the level of the control. At day 12 the MDMA 
group's activity was decreased relative to the control (consistent with a 5-HT depletion) 
while the M D W G M  1 group's activity was at or above that of the control. Biochemical 
analysis of brain tissue obtained from the animals sacrificed on day 7 or 14 following the 
beginning of the injections demonstrated a profound depletion of 5-HT, dopamine and 
norepinephrine with administration of MDMA. The MDMA/GMl group also showed this 
depletion, though to a smaller degree, suggesting some attenuation of toxic effects. 
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INTRODUCTION AND REVIEW OF THE LITERATURE 
Serotonin is a chemical substance found throughout nature. The actions of 
serotonin were originally discovered through observations of blood sera. Hillegaart ( 16) 
states that Stevens and Lee in the year 1884 and Brodie in the year 1900 observed that 
after blood clotted the remaining serum increased vascular tone, an observation that led 
directly to the name of the substance as serotonin. As Hillegaart points out (16), it was 
not until 1948, however, that Rapport et al. identified the specific chemical responsible 
for the initially observed vasoconstrictor qualities and assigned the name of 5- 
hydroxytryptamine (5-HT or serotonin) to that substance (Figure 1). 
Later discoveries demonstrated that 5-HT is found in a variety of locations in the 
body. Platelets, mast cells and the enterochromaffm cells of the intestinal mucosa all 
were shown to contain significant amounts of 5-HT (7). Platelets, which cannot produce 
5-FIT, actively take-up and appear to store 5-HT for release when the platelets are 
damaged. Serotonin released from damaged platelets has been implicated in platelet 
activation, in vascular smooth muscle cell and connective tissue cell proliferation, and in 
thrombus formation (43). In the intestines, serotonin is associated with the regulation of 
peristaltic activity of the intestines (43). Serotonin was also found in the nervous system 
of many organisms (16). Hillegaart points out that in 1953 Twarog and Page 
demonstrated the presence of 5-HT in the brain of mammals. As described in Hillegaart 
(16), in 1956 Bogdanski et al. and in 1957 Brodie and Shore independently suggested 
that serotonin is a neurotransmitter, based upon earlier evidence that 5-HT is not 
distributed uniformly throughout the brain. 
The serotonin produced outside the central nervous system cannot cross the 
bloodfbrain barrier. Consequently, the 1-2% of the body's 5-HT that is found in the 
3,4-Methy le nedioxy -methamp hehm ine 
Amp hetam i ne Serotonin J5HT) 
Dopamine Norep i nep hri ne 
Figure 1. Molecular Skucture ofMDMA, 
amp hetarnine, serotonin, dopamine, 
and norepinephrine. 
brain must be manufactured by saotonergic neuron S within the central nervous system. 
The precursor to 5-m, t ~ t o ~ h a n ,  is primarily obtained via dietary sources. 
Tryptophan that circulate in the blood competes with other neutral amino acids for active 
transport into the  brain across the bloodhrain barrier (7,43). Once across the barrier, 
tryptophan is taken up by nave cells which can then convert the amino acid to serotonin. 
Conversion beans when tryptophan is hydroxylated at the 5 position by the enzyme 
tryptophan hy drox y lase to produce 5-hy droxytryptophan. An amino acid decarboxy lase 
then removes t h e  ~ ~ b o x y l  group from 5-hydroxytryptophan, to produce 5- 
hydroxytryptamine (5-HT). Any excess serotonin is converted to 5-hydroxy indole 
acetic acid (5-HIAA) by rnonoamine oxidase and aldehyde dehydrogenase. 5-HIAA can 
then be transported out of the brain (7) and excreted by the kidneys. 
Elucidation of the neurotopography of serotonergic pathways was made possible 
by the fluorescent histochemical technique developed by Falck and Hillarp (7, 16) and 
refined through a combination of more recent techniques involving orthograde and 
retrograde tracking of immunohistochemically labeled 5-HT. 
Research has identified distinct groups of serotonergic neurons along or in close 
proximity to the midline or raphe areas of the pons and upper brain stem (7, 16, 43) . 
The original nine serotonergic nuclei (B 1-B9) described by Dahlstrom and Fuxe in 1964 
has been expanded to include 5-HT containing cells in the area postrema, the caudal locus 
ceruleus, and t h e  region in and around the interpeduncular nucleus (7). Lesioning and 
0flhoSadd rarograde tracing studies have shown that the more caudal cell goups (B 1 - 
B3) project to the  medulla and spinal cord, the more rostra1 cell groups (B7-B9) project to 
the telencepha]on and the diencephalon, and the intermediate 5-HT cell groups project in 
both ascending and descending directions (7, 16). 
The strudure and function of serotonergic cells are addressed by Whitaker- 
Azmitia (43, see also 7, 1 6). According to Whitaker-Azmitia, the serotonergic cells of 
rats begin to express their neurotransmitter phenotype as early as embryonic day 12. 
Whitaker-Azmitia also describes the 5-HT receptor types associated with serotonergic 
cells. The receptor types include three 5-HT 1 receptors (5-HI" 1 A, 1 B, 1 D)? three 5- 
HT2-type receptors (5-HTlc, 2 ~ ,  2 9 ,  and one 5-HT3 receptor. The 5-HT1 receptors 
work through second messengers that inhibit adenylate cyclase. Two of the 5-HT2 (5- 
HTlc, 2 ~ )  receptors have been shown to exert their effects by mediation of the second 
messengers inositol triphosphate and diacylglycerol. The mode of action of 5 -kIT2~ and 
the single 5-HT3 receptor types is unknown (43). 
The large number of 5-HT receptors would seem to suggest a highly complex rote 
for serotonin in the body. In fact, serotonin has been associated with a wide range of 
behaviors and psychological conditions (16,43). For example, serotonergic systems 
have been implicated in sexual and exploratory behavior as well as thennoregulation in 
laboratory rats (1 6). Whitaker-Azmitia (43) states that 5-HT also plays a role in the 
sleep-wake cycle, seizures, appetite, aggression, release of certain hormones, and 
circadian rhythms. These observations coincide with the assertions made by Cooper, 
Bloom, and Roth (7) that the serotonergic system mediates general homeostatic 
functions. Evidence also suggests that conditions such as migraine, eating disorders, 
affective illness, hyper-aggressive states, schizophrenia, depressive illness and suicidal 
behavior are accompanied by impaired or altered functions of serotonergic systems (15, 
41, 42, 43). 
Amphetamines and amphetamine-like drugs (Figure 1) affect specific 
neuropathways of the mammalian brain. Cooper, Bloom, and Roth (7) discuss the 
effects of amphetamine on catecholamine pathways in the brain. At the cellular level, the 
hypothesized modes of action for amphetamine fall into four categories (7, 18). 
Amphetamine may act as 1) an agonist at norepinepherine (NE) receptors, 2) an inhibitor 
of catecholamine reuptake, 3) a monoamine oxidase inhibitor, or 4) a promoter of NE and 
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dopamine (DA) release by a displacement process. Kandel and Schwartz (18) suggest 
that the most likely of the postulated mechanisms for amphetamine aciion includes 
promoting the release and blocking the reuptake of NE andor DA. Evidence indicates 
that prolonged administration of amphetamine leads to an inactivity of catecholamine 
neurons, presumably due to depletion of the transmitter substance. Whatever the 
mechanism may be, the net result of amphetamine action appears to be an initial increase 
in activity, followed by a long-term decrease in activity at affected synapses (5, 18). 
3,4-Methy lenediox y methamphetamine (MDMA, "Ecstasy, " empirical formula 
C11H 15N02 - Figure 1) is a ring-substituted phenylisopropylamine similar in nature to 
amphetamines and hallucinogens. Following the original patent of MDMA, issued in 
19 14 by the German company E. Merck (37), little attention was given to the drug until 
the last decade. The stimulant and psycho- mimetic effects of MDMA have made it a 
popular recreational drug as well as a controversial adjunct to psychotherapy (6, 12). 
The appeal of MDMA to some therapists rests on reports of lowered anxiety levels and 
reduced defensiveness in patients treated with MDMA (1 2). 
Studies have demonstrated drawbacks to casual use and treatment with MDMA 
(6, 1 1,24,34,35). Recreational use of the drug by humans has been directly linked to 
one death and secondarily associated with several other fatalities (6, 1 I). Series and 
coworkers (36) recently reported two cases, one a 24-year-old male and the other a 23- 
year-old female, that suggest recreational use of "Ecstasy" produces significant 
psychiatric disorders. Self-administration studies on MDMA (4, 37) suggest a high 
potential for abuse of the drug by humans and long-term use has been correlated with 
severe neurotoxicity (3, 6, 8,24). In fact, recognition of the adverse effects of MDMA 
led to it being classified as a schedule 1 drug. 
A relatively recent study by McCann et al. (25) demonstrates the dangers of 
MDMA use by humans. McCann et al. performed a controlled study in which humans 
were administered MDMA and measurements of biological and behavioral factors related 
to serotonergic function in the central nervous system were made. The measurements of 
5-hydroxy -indoleacetic acid levels in the CNS, as well as of the behavioral factors of 
impulsivity and indirect hostility, present substantial and significant evidence to support 
the assertion that MDMA is toxic to human beings. 
The specific mechanisms by which MDMA produces its effects are unclear. 
How eve, research using animal paradigms has offered insight into the neurocllemical 
effects and neurotoxicity of MDMA. For example, evidence gathered using animal 
models indicates that it is unlikely that MDMA is transported into nerve terminals via 
carrier-mediated processes (26,3 1,33). Because MDMA does not appear to be taken 
directly into cells, other modes of action have been postulated. Receptor-mediated 
actions offer a possible alternative mode of action for MDMA. The affinity of MDMA 
and its optical isomers for various receptors and receptor subtypes has been examined by 
several researchers. The R(-)-MDMA isomer has been shown to have a higher affinity 
for examined receptors than the S(+)-MDMA isomer or racemic MDMA (20). In general, 
MDMA shows the greatest affinity (Ki 0.6 +I- 0.05 uM) for serotonergic uptake 
receptors; it shows less affinity for ~ - H T ~ A ,  1 ~ ,  ID, and 2~ receptors and the 
adrenergic a2, b, and al ;  it shows even less affinity for the dopaminergic receptors D2 
and Dl (4, 20). 
Toxic metabolites may also be involved in the neurotoxicity produced by MDMA. 
There are several arguments for and against the role of toxic metabolites of one form or 
another in MDMA induced neurotoxicity. McKenna and Pmoutka (26) suggest that 
because 5-HT uptake inhibitors block MDMA-induced neurotoxicity (29, 30) and only 
systemic administration of MDMA (as distinct from intracerebra1 administration) 
produces neurotoxicity, toxic metabolites of MDMA appear to be involved. Yeh and Hsu 
(44) offer evidence in opposition to the hypothesis that toxic metabolites are involved: 
these researchers demonstrated that the neurotoxic effects of MDMA are much more 
profound than the toxic effects of the metabolites of MDMA. McKenna and Peroutka 
(26) offer another suggestion; they propose that MDMA-induced neurotoxicity might be 
due to toxic metabolites produced by degradation of dopamine @A) rather than 
metabolites of MDMA. They argue that MDMA may cause inhibition of the enzyme 
monoamine oxidase and thus allow increased levels of DA around 5-HT neurons. The 
DA is then presumably taken up and metabolized to cytotoxic metabolites via oxidative 
processes. The suggested role of DA involvement in MDMA induced serotonergic 
toxicity stems from research done by Stone et al. in 1988 (38). Stone and coworkers 
demonstrated that by depleting the DA content in the central nervous system by 
administering a-methyl-p-tyrosine to block DA synthesis, they could significantly reduce 
the short- and long-term neurotoxic effects of MDMA. 
McKenna and Peroutka (26, see also 32) divide the neurochemical effects of 
MDMA into acute (c 24 hrs.) and long-term (> 24 hrs.) stages. The acute effects include 
decreased tryptophan hydroxylase (TPH) activity as well as significantly decreased brain 
concentrations of 5- h y droxytr yptamine (5-HT) and 5- hy droxy indoleacetic acid (5 - 
HIAA). The low concentration of brain hy droxy indoles, thought to be related to massive 
neuronal release of 5-HT, return to normal levels within 24 hours. After the first 24 
hours, MDM A causes several long-term neurochemical effects. For example, following 
the initial return to normal levels, 5-HT and 5-HIAA concentrations follow a slow and 
regular decrease. Long-term effects of MDMA are further characterized by a persistent 
decrease in TPH activity and a decrease in 5-HT terminal concentrations (26). In 
summary, the long-tam neurochemical effects are indicative of severe serotonergic 
depletion. Distinct from amphetamine, which affects catecholamine pathways, the severe 
damage incurred by systemic MDM A administration has been shown to include 
degeneration of fine serotonergc axons in cortical, hiwarnpal, and smatal brain 
regions (2). As extensive as the axonal damage is, the pattern of damage suggests that 
the toxic effects of MDMA do not involve cell death - this fact raises the question of 
whether or not it would be possible to genmate new fibers to replace those previously 
damaged. 
Repair of neuronal damage in the central and peripheral nervous systems involves 
enhancing neuroplasticity mechanisms inherent in the systems and the cells of the 
systems. Complex biological molecules called gangliosides demonstrate the ability to 
trigger neurotrophic and neuroprotective effects associated with general neuroplasticity. 
Gangliosides are glycosphingolipids with a short carbohydrate chain attached to a 
lipophilic (hydrophobic) tail consisting of an amino dmhol sphingosine and a fatty acid. 
Research on the effects of the neutral lipid monosialoganglioside GM1 on neural fibers of 
the central nervous system has demonstrated that it offers protection against physical and 
chemical damage (22,23,27). 
Evidence in favor of the efficacy of treatment with gangliosides and, specifically, 
GM1 can be found in studies on the effects of GM 1 in facilitation of recovery from 
various nervous system injuries. The neuroplasticity enhancing affects of GM 1 have 
been examined in cases ranging from chemical (9, 10, 13, 19,2 1) and physical lesions 
(5) to injury resulting from ischemic stroke (1, 17). 
Endogenous GM1 is a normal component of cell membranes but is especially 
prevalent in the CNS, where it is associated with a multitude of physiological activities 
involving these membranes. GM 1 is thought to exert its affects once incorporated into 
the cell membrane. In fact, exogenously administered GM 1 has been shown to be 
efficiently incorporated into isolated neuronal membranes in vitro (27). Although the  
specific mechanisms responsible for the observed neurotrophic and neuroprotective 
effects of GM1 are not known, research has shown several general modes of action. For 
example, GM 1 inhibits neuronal fiber degeneration and accelerates functional 
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sy naptogenesis in lesioned tissue (22,27). Studies (19,23) demonstrate that GM 1 
inhibits neuronal damage mediated by excitatory amino acids. Specifically, Manev et al. 
(23) discuss a mechanism by which GM1 protects neurons from chemical (glutamate)- 
induced necrosis. Manev and coworkers (23) postulate that exogenously administered 
gangliosides such as GMl are incorporated into the cell membrane where they inhibit 
protein kinase C destablization of ca2+ homeostasis in the cell. Inhibition of protein 
kinase C appears to be due to a direct blockade of the cascade of which the kinase is a 
part. Since ~ a 2 +  levels are closely related to necrosis caused by excessive stimulation by 
excitatory amino acids (ie. glutamate), prevention of the destablization prevents the 
glut amate-induced toxicity. Other possible mechanisms by which GM 1 facilitates 
neuroplasticity can be found in research that demonstrates that treatment with GM 1 
increases ATPase activity, enhances protein phosphorylation, promotes neurite 
outgrowth and prolongs in vino survival of isolated neurons (27). 
The demonstrated protective and neurotrophic abilities of GM 1 implicate it as a 
possible treatment for a wide range of physical lesions and as a possible antagonist to the 
effects of drugs shown to have neurotoxic tendencies. 
The purpose of this study was to explore the hypothesis that the rate of recovery 
from MDMA-induced serotonergic neurotoxi city could be enhanced via collateral action of 
the ganglioside GM 1 by its reported neurotrophic properties. 
MATERlALS AND METHODS 
Experimental Design 
This study was designed to examine the efficacy of systemically administered GM 1 
to attenuate the neurotoxic effects of MDMA on the rat brain. Male Sprague-Dawley rats 
(250g to 350g) were used in a 4 X 2 block style experimental design. The treatment 
groups included: a) saline solution (0.9%), b) MDMA, C) GMl and d) MDMA + GM 1. 
Animals were sacrificed either 7 or 14 days following the beginning of the drug treatment. 
All drugs were administered by intraperitoneal injections in volumes of 0.2-0.3 ml. 
MDMA obtained from Research Biochemicals International (RBI, Natick, MA) was 
administered at a dose of 20 mg/kg once a day for four days. GMl (kindly provided by 
FIDIA Pharmaceuticals, Italy) was administered as a single 40 mgkg dose. When given 
concomitant with MDMA, GM 1 was administered on the first day of the MDMA treatment. 
Five animals per treatment group per sacrifice day were used for a total of 40 animals. 
Table 1 depicts the research design. 
Table I. The various parameters of the experiment including treatment , sacrifice day, and 
number of animals used for each phase of the experiment 
Behavioral Activity 
The behavioral activity study was paformed in the familiar surroundings of the 
animal care facility. A 12-hour lighvdark cycle was maintained and ambient room 
temperature was held at a constant 74O F (k 2 O ) .  Animals were placed in clear plastic cages 
with free access to food and water between 12:00 PM and 1:00 PM at day 5 or day 12 
following the first day of injections. Each cage was placed on a Stoelting electromagnetic 
activity monitor that recorded the movements of the animals. The activity of the animals 
was measured in the form of the number of movements each animal made in 6-minute 
epochs throughout the 24-hour paiod on the monitor. The activity per 6-minute epoch was 
summed to give the total activity for each hour during the 24-hour period. The average 
activity, per hour, was then determined for each treatment group. At the conclusion of the 
activity monitoring period the animals were returned to their home cages until they were 
used for the biochemical analysis. 
Data collected was analyzed using ANOVA and Tukey statistical tests when 
appropriate. 
Biochemical Analysis 
At day 7 or day 14 following the first day of injections, the rats from the behavioral 
activity analysis (24 hours after the behavioral activity study) were anesthetized with 
sodium pentobarbital (30 mg/kg) and sacrificed by cervical dislocation. The brains were 
then removed and the frontal cortex, lateral cortex (containing the hippocampus), 
stnaturn/midbrain, cerebellum, and brainstem regions were separated by dissection (see 
Figure 2). Throughout the dissection, the brains were kept on ice and following dissection 
each region was weighed and stored at -700 C until assayed. 
Fmntd Cortex I 
Bminstern I 
Spinal Cord \ 
C ere b ell urn 
Figure 2. Diagram indicating cuts to obtain the brain 
regions to be analyzed. Patterned lines indicate 
cuts made. Regions include bra instern, lateral 
hemispheres, cerebe il urn, ko nta I cortex, and 
midbrain. 
Preparation and assay of the samples were according to methods described by 
Saller and Salama (28, see also 39, 40). At the time of the assay, samples were placed in 
sonication cuvettes containing 38 volumes (volume = vol = the mass, in grams, of the 
tissue sample converted to a volume, in rnillileters) homogenization buffer and 2 vol of an 
internal standard. The homogenization buffer contained 7 vol 0.1 M monobasic sodium 
phosphate (pH 4.0) with 1 mM disodiurn EDTA and 1 m M  sodium octanesulfonic acid and 
3 vol acetonitrile. The internal standard, isoproternol, was added to 2 vol of the buffer, 
which was then added to the sample. Homogenization of the sample was accomplished 
with a W- 185 sonicator (Heat Sy stems-Ultrasonics Inc., Plainview, NY). Following 
sonication, the samples were placed in 15 ml glass centrifuge tubes and centrifuged at 
10,000 rpm for 10 minutes. A portion of the supematant was removed from each sample 
and frozen at -700 C until the time of the assay. 
Before the HPLC assay the samples were thawed and re-centrifuged. The samples 
were then analyzed for serotonin (5-HT), 5-hy droxy indolacetic acid (5-HIAA), 
norepinepherine (NE), dopamine (DA), and dioxy pheny lacetic acid (DOP AC) using high 
performance liquid chromatography techniques that employed an electrochemical detection 
system. A small portion (20 p1) of each sample was manually injected using a Beckrnan 
2 10A injector (Beckman Instruments, Inc. Berkley , CA). Following injection, the sample 
passed through a 0.46 X 4.5 cm guard column and then through an Altex 5-pm, 0.46 X 25 
cm C 1 8 Ultrasphere reverse-phase column (Beckman Instruments, Inc.). Electrochemical 
detection was was accomplished as the column effluent passed through a Bio-Rad Model 
1340 electrochemical detector (Bio-Rad Laboratories, Hercules, CA) with a 0.65 V 
electrical potential applied to the working electrode. The resultant peak information was 
integrated by a Hewlett-Packard Model 3392a integrator (Hewlett-Packard Co., Avondale. 
PA). Dr. Dean Hoganson at Drake University supervised the biochemical analysis 
procedure. 
Collected data was analyzed using ANOVA and Tukey statistical tests when 
appropriate. 
This research protocol was reviewed and approved by the Institutional Animal Care 
and Use Committee at the University of Osteopathic Medicine and Health Science. The 
methods were found to meet the revised policy on the care of animals in neuroscience 
research (Society for Neuroscience). 
RESULTS 
Behavioral Activity 
The average activity (measured as movements) for the animals in each treatment 
group for the full 24-hour period is depicted graphically in Figures 3b and 4b. As can be 
seen, at both day 5 and day 12 following the beginning of the treatments, the animals 
showed an initially high level of activity that decreased to a lower less variable level. The 
initial high level of acitivity corresponds to the normal exploratory behavior of the animals, 
while the decrease and levelling off reflects the acclimation of the animals to their 
surroundings. Furthermore, as Figures 3b and 4b suggest the greatest variability among 
treatment groups can be found during the exploratory phase of the animals. 
An ANOVA and multiple comparisons (Tukey) analysis of the data collected 
throughout the behavioral study demonstrated that the majority of the significant differences 
between treatment groups fell within the frst 5 hours (13:OO to 17:OO) of activity for both 
day 5 and day 12. As a result of the statistical analysis for the behavioral data collected for 
the full 24 hour period, attention was focused on analyzing the statistically significant 
differences found within the animals' exploratory phase (Tables 2-5 and Figures 3a-4a). 
Figure 3. Average summed behavioral activity at day (in movemenh) 
For each katment group ror the first rive hours (a.) and the 
full 24 hour period (b.). 
DAY 11 2 
Figure 4. Average summed behavioral activity at day 1 2 (in movements) 
for each Featme n t group for the first Five hours (a. 
24 ho ur period (b .). 
At day 5 ,  t h e  first five hours of activity (Tables 2-3 and Figure 3a) of the animals 
fall within two distinct categories based on statistical similarities and differences. The fist 
category includes the activity of the GMl and MDMA groups. The summed activity for the 
fist hour of each of these groups falls between 500 and 600 movements and drops to 
between 200 and 3 0 0  movements by the fifth hour. Compared to one another, the GM1 
and MDMA treated animals do not show significantly different levels of activity within the 
first five-hour period. However, the activity of the GM 1 and MDMA treated animals is 
significantly greater than the level of activity expressed by the controts and the MDMA + 
GMl treated animals. The control and collateral treatment groups (MDMA + GM 1) make 
up the second category of activity, in that they are not significantly different from each 
other but are significantly lower than the GM 1 and MDMA groups. The activity level of 
those animals in the second category begins at approximately 300 movements in the first 
hour and drops to between 50 and 100 movements by the fifth hour. 
In the first five hours at day 12 (Table 4-5 and Figure 4a), the activity of the control 
animals, those animals treated with GM 1, and those animals that received collateral 
treatment were not significantly different from each other, however, they were all 
significantly greats than the level of activity of the MDMA treated animals. In the first 
hour, the average activity was approximately 1 490 movements for the animals treated with 
GMl, 1000 movements for the controls and collaterally treated animals, and 300 
movements for the MDMA treated animals. By the fifth hour, the level of activity of each 
group had dropped slightly. 
Despite the  12-hour light-dark cycle, no noticable change in activity level was 
observed corresponding to the light and dark periods. 
Table 2. Behavioral activity at day 5 for the first 5 hours 
Data are mean + SD. Time indicated is fkom a 24 hour scale. Control = the saline controls, 
GM 1 = group given the GM 1 alone treatment, MDMA = group given the MDMA alone 
treatment and MDMA + GM 1 = the collateral treatment group. 
Treatment Time 
13:OO 14:OO 15:OO 16:OO 17:OO 
Table 3. ANOVA of behavioral activity in the first five hours at day 5 
Control 
GMl 
MDMA 
MDMA + GM 1 
Time (hours 13:00- 15:W on a 24 hour scale) by treatment (control, GM 1, MDMA, and 
MDMA + GM 1). SS = sum of squares, df = degrees of freedom, M S  = mean of squares, 
F = F-value and P-value = P-value. Tukey's multi-comparisons test showed that there 
were significant differences between the controls and the GM 1 treated groups, the controls 
and the MDMA treatment group, the GM 1 group and the MDMA + GM 1 goup, as well as 
the MDM* group and the MDMA + GM 1. 
142f253 
357 rt 277 
532+,225 
200rt181 
321k276 
589 k 339 
5114f150 
427f255 
SS d f MS F P-value 
34 f 47 
347 f 315 
446k219 
104 f 39 
7.2OE-06 
2.1 OE-06 
0.9 
A 
8.7 
1 1.6 
0.6 
Time 
Treatment 
Interaction 
Within 
Total 
16 3- 16 
225 + 241 
167f172 
87 f 48 
30+51 
15 1 f 107 
240f252 
70 + 15 
334572.4 
448903.2 
22298.6 
38548.3 
1338289.5 
1 3 46709.5 
267582.6 
3083863.2 
6036444.8 
4 
3 
12 
80 
99 
Table 4. Behavioral activity at day 12 for the first 5 hours 
Treatment Time 
13:OO 14:OO 15:OO 16:OO 17:OO 
Control 1040 t 577 663k.462 5323512 220k199 146 f 63 
GM1 1452 t 698 1084 k 483 823 k 338 395 f 485 378 + 243 
MDMA 272 k 331 163 + 68 150 k 53 138k 66 179 + 113 
MDMA + GM1 1004 k 342 874 k 469 903 2714 601 f 196 213 k 136 , 
Data are means + SD. Time indicated is from a 24 hour scale. Control = the saline 
controls, GM 1 = group given the GM 1 alone treatment, MDMA = group given the MDMA 
alone treatment and MDMA + GM1 = the mllateral treatment group. 
Table 5. ANOVA of behavioral activity in the first 5 hours at day 12 
SS d f MS F P-value 
Time 1338289.5 4 334572.4 8.7 7.20E-06 
Treat ment 1346709.5 3 448903.2 11.6 2.1OE-06 
Interaction 267582.6 12 22298.6 0.6 0.9 
Within 3083863.2 80 38548.3 
Total 6036444.8 99 
Time (hours 13:OO- 15:00 on a 24 hour scale) by treatment (control, GM 1, MDMA, and 
MDMA + GM l).SS = sum of squares, df = degrees of freedom, MS = mean of squares, F 
= F-value and P-value = P-value. Tukey's multi-comparisons test showed that there were 
significant differences between the controls and each of the other treatment goups 
(MDMA, GM1, and MDMA + GMl), between the GM1 group and the MDMA group, and 
between the MDMA group and the MDMA + GM 1 group. 
Biochemical Analysis 
Brain tissue from the different regions (brainstem = BS, lateral hemispheres = LH, 
cerebellum = CB, frontal cortex = FC, and midbrain = MB; see Figure 2) was assayed for 
serotonin (5-HT), dopamine (DA), norepinephrine (NE), 5-hy droxy indoleacetic acid (5- 
HIAA), and dioxyphenylacetic acid (DOPAC). The results of the assays are given in 
Tables 6-10 and graphically depicted in Figures 5-9. 
Concentrations of the neurotransmitters and related metabolites within the control 
groups varied by region as would be expected. 5-HT concentration was the greatest in the 
midbrain region corresponding to the raphe. NE concentrations of 400-500 ugfgm were 
observed in the brainstem and midbrain regions which contain the locus ceruleus. The 
greatest concentrations of DA were found in the lateral hemispheres and the midbrain, 
slices which were likely to contain part or all of the striaturn and substantia nigra. 5-HIAA 
was found in relatively high concentrations in all of the tissues except the cerebellum and 
obsaved to be regionally distributed in a manner similar to its parent transmitter, 5-HT. 
The concentration of DOPAC, on the other hand, was minimal to non-existent in all of the 
tissues examined. 
In every tissue region analyzed, the MDMA treatment significantly reduced the 
neurotransmitter (5-HT, NE, and DA) concentrations at both day 7 and day 14. For 5-HT 
and NE, the GM 1 treatment also significantly reduced the transmitter concentrations at day 
7 and day 14. The collateral treatment group (MDMA+GM 1) showed an appreciable, albeit 
non-significant, attenuation of the MDMA-induced reduction of the transmitters 5-HT, DA, 
and m. The most dramatic effects were observed for the DA (see Figure 6). 
The concentration of the metabolite of 5-HT (5-HIAA) was reduced by MDMA and 
MDMA + GM 1 treatments. Interestingly, there was little or no effect with GM 1 treatment 
and no appreciable attenuation of MDMA effect by the collateral treatment with GM 1. 
Sample Day 7 Day 14 
Brainstem [5-HT] ug/gm Std. Dev. [5-HT] ug/gm Std. Dev. 
CONTROL 1 92.4 k1 54.7 352 k44.82 
GM1 55.6 558.1 8 1 04.6 k97.59 X 
MDMA 1 k2.24 X 9.8 k16.04 X 
MDMA + GM1 23.2 k51.88 X 29 k41.69 X 
Lateral hemispheres 
CONTROL 264 256.97 297.5 595.57 
GM1 1 12.4 258.93 X 193 k32.78 
MDMA 36.6 k24.13 X 45.8 k78.59 X 
MDMA + GM1 52.8 k75.3 X 91.6 k64.23 X 
Cerebellum 
CONTROL 36 k1  6.55 59.25 +I 8.43 
GM1 1 5.6 k28.18 4 28.94 X 
MDMA 0 +-0 X 0 +o X 
MDMA + GM1 0 20 X 26.2 k1 6.98 X 
Frontal Cortex 
CONTROL 128.6 k78.67 1 64.5 597.1 9 
GM1 28.2 23 5.07 56 k64.85 
MDMA 0.8 21.79 X 8.6 21 9.23 X 
MDMA + GM1 4.4 k9.84 X 1.4 +I .95 X 
Midbra~n 
CONTROL 335.4 21 45.9 550.25 +I 82.7 
GM1 297.8 21 1 0.2 31 7.4 +I 76.5 
MDMA 11.4 k25.5 X 1 27.2 k42.6 X 
MDMA + GM1 71.4 k60.5 X 127.2 297.2 X 
l'ahle 0: Serotonin (5-11'1') (.onc.en~;ltion (ug/gm of tissue, wet weight) at 
da) 7 and 14 tor each of the treatment groups by brain region 
analyzed: X = signific-antl) different from control ( p < 0.05 1. 
Sample Day 7 Day 14 
Brainstem [DA] ug/gm Std. Dev. [DA] ug/gm Std. Dev. 
CONTROL 57.8 229.98 30 k12.14 
GM 1 0 +O X 3.4 rt7.6 
MDMA 0 +,O X 5 k1 1.1 8 
MDMA + GM1 6 28.49 X 1 6.4 k27.32 
Lateral hemispheres 
CONTROL 404 2213 480.75 k267.1 
GM 1 283.6 2260.6 256.8 21 80.4 
MDMA 136.8 +I 19.6 65.8 f 68.5 
MDMA + GM1 321 k429.3 427.8 k324.3 
Cerebellum 
CONTROL 4.2 k9.39 1 1.25 k14.73 
GM 1 13.4 +I 4.03 0 +0 
MDMA 12.2 21 2.36 4.8 k1  0.73 
MDMA + GM1 4.4 29.84 33 236.1 1 
Frontal Cortex 
CONTROL 207 k276.4 269.75 k253.1 
GMI 28.8 k23.2 26.8 k21.1 
MDMA 10.8 21 7.4 16.4 rt28.6 
MDMA + GM1 18.2 21 3 11.6 k10.9 
Midbra~n 
CONTROL 260.2 k63.5 61 7 2443.6 
GM 1 323 2248.9 397.8 2243.8 
MDMA 61.2 k50.8 1 76.4 + I  54  
MDMA + GM1 141 21 10.3 21 5.4 k214.9 
'I'able 7: Dopamine ([)A) c-oncentration (ug/gm 01' tissue, wet weight) a t  
day 7 and 1 4 for each of  the treatment groups bj- brain region 
analyzed; X = (iignificantly different from control ( p  < O.05f 
'I'ahle 8: Norepinephrine (NCI) c-onr.enuation (ug/gm of tissue, wet weight) at 
day 7 and 14 Sor each o f  the treatment grr~ups bq brain region 
anal> zed: X = signific-anily different from c-ontrol ( p  < 0.05) 
# 
Sample Day 7 Day 14 
Brainstem [NE] ug/grn Std. Dev. [NE] ug/gm Std. Dev. 
CONTROL 427.4 21 84.63 498.75 k49.28 
GM1 5 1 k60.67 X 99.4 284.53 X 
MDMA 2.2 24.92 X 0 +C X 
MDMA + GM1 38 k38.24 X 35.6 k56.01 X 
Lateral hemispheres 
CONTROL 1 64.2 k36.97 223.25 k30.41 
GM1 50.4 220.4 X 74.2 +I 4.1 X 
MDMA 32 k21.83 X 22.6 k1  6.79 X 
MDMA + GM1 64.8 k63.61 X 85 k39.29 X 
Cerebellum 
CONTROL 82.2 228.88 105.75 k 1 4.06 
GM 1 3 4.8 k37.33 16.4 k29.94 X 
MDMA 6.2 k1 3.86 X 17.8 k26.44 X 
MDMA + GMI 22.2 231.86 X 55.4 rt34.46 
1 
Frontal Cortex 
CONTROL 1 34.6 k84.98 11 6.75 k82.27 
GM 1 27.2 k17.75 X 28.8 k32.95 
MDMA 6 k9.59 X 5.4 k12.07 X 
MDMA + GM1 
Midbrain 
CONTROL 
GM1 
MDMA 
MDMA + GM1 
11.2 51 5.74 X 
448.8 k82.9 
161 -2  k14.1 X 
36.2 k34.82 X 
108.4 285.44 X 
8.6 21 2.64 X 
575.75 k1  63.07 
167.2 k82.86 X 
1 30.8 st48.58 X 
136.6 +I 07.46 X 
'I'able 0: -5-hydro~yindoleacetic acid ( 5 - H l M j  concentration (ug/gm of tissue, wet 
weight) at  day 7 and 14 for each of the treatment groups bj brain region 
analyzed; X = significantly different from control ( p  < 0 . 0 5  j; 
= significantly different from (;bI I treatment group. 
MDMA + GM1 
MDMA 28.8 k64.4 6.8 f l 5 . 21  
MDMA + GM1 40.8 k42.52 54.8 k69.97 
Frontal Cortex 
CONTROL 68 k1 17.8 0 k0 
GM1 250.2 kS01.6 205.2 +,I 95.2 
MDMA 72.8 51 62.8 33.2 k50.5 
MDMA + GM1 145 k160.8 351.6 1552.1 
Midbrain 
CONTROL 7.8 k17.4 34.5 k39.9 
GM1 472.6 k243.2 658.6 +I 18.6 
MDMA 261 k416.8 260.8 +I 42.3 
MDMA + GMI 91 6.6 kS49.4 X 503.6 2300.4 
L 
l'ablc 1 0 :  1)ioxyphcnq lacetic acid (I)OPAC) roncun t r a t io~~  (ug/gm o f  tissue, wet 
weight) at daj 7 and I  fhr each o f  the treatment groups b j  brain region 
analyzed; X = ~ignif'icantl> different from c-ontrol ( p  < 0.05) 
1 
I---- - ~ ~ ~ ~ ~ ~ * ~  5 - H i  - Day 7 
Figure 5. Avemge concenhtion of: 5-HT for each of the brain regions 
analyzed. BS= Brainstem, LH=Lateral Hemispheres 
CB=Cerebellum, FC=Fronbl Cortex, and MBzMidbmin. 
A.) Animals sacrificed 7 days folbwing the beginning of 
injections. B.) Animals sacrificed 14 days following the 
beginning of injections. 
?-"-,=a 
DA- Day 7 
DA- Day 14 
Figure 6.  Average concenktion of dopamine (DA) for each of the brain 
regions analyzed. B S= Brai nstern, L H=Lateral Hemispheres 
CB=Cerebellum, FC=Fronhl Cortex, and MB=Midbrain. 
A,) Animals sacrificed 7 days following the beginning of 
injections. B .) Animals sacrificed 1 4 days following the 
beginning of injections. 
Figure 7 .  Average concenb-ation of norepinephrine (HE) for each of the brain 
reg ics ns ana ly zed. B S = Bra instern, L H- Latera l Hemispheres 
CB=Cerebellum, FC=Frankl Cortex, and MB=Midbmin. 
Animals sacrificed 7 days Following the beginning OF 
injections. B.) Animals sacrificed 14 days following the 
beginning ol' injections, 
5 - H I A A  - Day 7 
5-HIAA - Day 14 
Figure 8. Average co nce nb-atio n of 5- H lAA for each of the brain regions 
analyzed . B S= Brainstem, LH= Lateral Hemisp heres 
CB=Cerebellum, FC=Fronhl Cortex, and MB=Midbrain. 
A.) Animals sacrificed 7 days rollowing the beginning of 
injections. B.) Animals sacrficed 1 4 days following the 
beginning of injections. 
DOPAC- Day 7 
P - a - E P -  
Canival a Gbd 1 MDMA 0 MDMA+GM 1 
B" 
DEIPAC- Day 14 
Figure 9. Average concenb-ation of' DQPAC for each of the brain 
regions analyzed. 8 3 = Bra instem, L H= Latern l Hemispheres 
CB= Cerebell um, F G=Fronhl Cortex, and MB=M idbra in. 
A.) Animals sacrificed 7 days fallowing the beginning of 
injections. €3.) Animals sacrificed 1 4 days following the 
beginning of. injections. 
There were no significant differences in the concentration of 5-HIAA between day 7 and 
day 14. 
DOPAC (the metabolite of DA) concentrations found in each of the treatment 
groups were elevated over the concentrations in the control group and relatively consistent 
from day 7 to day 14. The most profound increase in DOPAC concentration was in the 
GM 1 and collateral treatment groups. 
ANOVA and Tukey analysis of the biochemical data indicated that there were 
significant differences in the concentrations of the various substances examined, on a 
treatment and region dependent basis (see Tables 6- 19). 
The regions examined for 5-HT contained differing concentrations of the 
neurotransmitter depending on the treatment (see Table 6 and Figure 5). The concentration 
of 5-HT found in each of the regions from the day 7 and day 14 MDMA groups was found 
to be significantly different from controls by ANOVA and Tukey analysis. Serotonin 
concentrations were also significantly different in the MDMA + GM1 groups. The GM 1 
alone treatment produced concentrations of serotonin statistically different from controls in 
three instances: LH day 7, BS day 14, and CB day 14. 
As can be seen in Table 7 and Figure 6,  significantly different concentrations of 
dopamine (DA) were only found between the brainstems of day 7 controls and each of the 
day 7 treatment groups. With respect to norepinephrine concentrations, in all but three 
cases the concentration of the neurotransmitter was significantly different from controls. 
The three exceptions were the CB of GM 1 (day 7) animals, the CB of MDMA + GM 1 (day 
14) animals, and the FC of GM 1 (day 14) animals (see Table 8 and Figure 7). 
Significantly different concentrations of 5-HIAA were, in all but one case, found 
between GM1 treated animals and other treatment groups. The concentrations of 5-HIAA 
found at day 7 post treatment in the brainstem of MDMA and MDMA + GM 1 treated 
animals were statistically different from the concentration found in the brainstem of GM 1 
treated animals (Table 9). In the brainstem at day 14 post treatment, however, the only 
significant difference in 5-HIAA concentration was between the GM 1 treated animals and 
the MDMA treated animals. The cerebellums of the MDMA group and the MDMA + GM 1 
group examined at day 7 and day 14 for 5-HIAA were found to contain significantly 
different concentrations of 5-HIAA relative to the concentration of 5-HIAA in the 
cerebellums of the GM1 treated group. The concentration of 5-HIAA in the control group 
was statistically different from another group in only one case, and that was at day 14 post 
treatment in the lateral hemispheres of the MDMA + GMl treatment group. 
Table 10 and Figure 9 show that midbrain corlcentrations of DOPAC were found to 
be statistically different between the controls (day 7) and the collateral treatment group (day 
7) 
DISCUSSION 
As shown in Figure 3a, the activity of the animals at day five indicates that the 
MDMA alone treatment produced a significant hyperactivity relative to the control. The 
elevated level of activity observed in those animals treated with MDMA alone is a result 
consistent with the effects the neurotransmitter release induced by the recent administration 
of MDMA. Specifically, the serotonergic system has been implicated in exploratory 
behavior of rats (1 6), therefore, increasing the release of serotonin by treatment with 
MDMA should cause a corresponding increase in exploratory activity. The collateral 
treatment group (MDMA + GM I), however, displayed a level of activity not significantly 
different from the level of activity displayed by the control group. Those animals treated 
with GM 1 alone also showed a significant increase in activity when compared to the control 
group. 
33 
An examination of the first five hours of activity at day 12 (Figure 4a), showed that 
the MDMA alone treated animals displayed a marked reduction in the level of activity 
relative to the controls. The reduced level of activity is entirely consistent with a depletion 
of neurotransmitters as a result of the long-term neurotoxic effects of chronic administration 
of MDMA. Decreased activity of the serotonergic system due to MDMA treatment might be 
directly related to a decrease in the exploratory behavior of the rats. At day 12 the collateral 
treatment group showed a level of activity above the control group. As at day rive, the 
level of activity displayed by those animals treated with GM 1 alone, and examined at day 
12, was markedly elevated relative to the controls. 
In general, the level of activity was found to be much higher during the exploratory 
period of the animals at day 12 than during the exploratory period of the animals at day 5. 
The dissimilarity between the level of activity of the two groups of animals might be 
explained as being a difference in the disposition of the animals in each group. 
The 12-hour light dark cycle was not reflected in the activity level of the animals 
(both day 7 and day 14). A possible explanation- for this result could be that the animals 
were kept in a room that was adjacent to a larger area that housed dogs and the activity of 
the dogs may have affected the behavior of the rats. 
The biochemical data shows that certain non-significant trends in neurotransmitter 
concentration predominate. Relative to the wntrol groups, the concentration of each of the 
neurotransmitters examined was reduced in almost all of the tissues fiom animals treated 
with MDMA alone. The lower concentrations of neurotransmitters observed at day 7 are 
consistent with the depletion of neurotransmitters associated with the chronic phase (> 24 
hours) of MDMA treatment (26). The reduced concentration of neurotransmitters at day 1 4 
seems to be indicative of an insufficient amount of time to fully recover from the chronic 
effects of MDMA treatment. As the concentration of neurotransmitters found in the tissues 
taken from the collateral treatment group was consistently greater than the concentration of 
the same neurotransmitters in the MDMA alone treatment group, it appears that GM1 is 
exerting an attenuating effect on the neurotoxicity of MDMA treatment or enhancing the rate 
of recovery. Although the amount of neurotransmitters found in the tissues of the collateral 
treatment group were still lower than the levels observed in the control group, the amounts 
were, for the most part, between the control group and the MDMA treatment group. Those 
tissues taken from animals treated with GM 1 alone showed concentrations of 
neurotransmitters slightly lower than the controls in the majority of the tissues examined, a 
result which may be related to the neurotrophic actions of GM 1. Another explanation for 
the lower transmitter concentrations found for the GM 1 treatment group might be found in 
our method. The GMl tissues were processed at the beginning of the study and were 
temporarily stored in a - 100 F freezer (a step that was not necessary with the other 
samples). The time in the fieezer could have allowed degradation of the transmitter 
substance. To evaluate this possibility, the GM1 biochemical analysis will be repeated. 
ANOVA and Tukey analyses of the biochemistry data indicated that the 
concentrations of each of the neurotransmitters found in the tissues from the three treatment 
groups (MDMA, GM1, and MDMA + GM1) were, in general, significantly different from 
the concentrations of neurotransmitters found in the control tissues. These trends can be 
seen graphically in Figures 5-9. 
The concentrations of serotonin, dopamine, and norepinephrine provides 
substantial evidence indicative of the trends out lined above. For example, the serotonin 
concentrations in tissues at day 7 and 14 (Table 6 and Figure 5) clearly follow these trends. 
Specifically, for the MDMA alone treated animals, the concentration of 5-HT was 
significantly lower than the concentration of 5-HT in the tissue samples collected from the 
control animals. A comparison of the concentrations of 5-HT between the tissues of the 
MDMA alone heated animals and the GM 1 alone treated animals showed a statistically 
insignificant trend: The concentration of 5-HT found in most of the tissues examined from 
the MDMA treated animals was lower than the concentration of 5-HT found in the tissues 
taken from the MDMA + GM1 treated animals. Furthermore, this trend can be seen at day 
7 and day 14. Examining the data collected for NE and DA reveals similar trends. The 
similarities between the three neurotransmitters (5-HT, DA, and NE) are not surprising 
when one considers that one of the hypothesized modes of action by which MDMA 
produces its toxic effects is through an action on dopaminergic neurons which may then 
affect associated 5-HT andor NE neurons. 
There appears to be a trend in the concentrations of the neurotransmitters when the 
MDMA and MDMA + GM 1 treatments are compared at day 7 and day 14. Tables 6-8 
show that both MDMA and MDMA + GM I treatments generally show an increase in the 
concentration of each of the neurotransmitters fkom day 7 to day 14. The MDMA + GM 1 
group, however, appears to show a greater and more consistent increase from day 7 to day 
14 than the increase seen in the MDMA treatment group. That this trend exists would seem 
to suggest that the GMl oollateaal treatment may enhance the rate of recovery fkom MDMA- 
induced toxicity with respect to the neurotransmitters that were examined. 
Two general observations can be made with respect to the metabolites of 5-HT (5- 
HIAA) and DA (DOPAC). Treatment with MDMA or the collateral treatment decreased the 
concentration of 5-HIAA but increased the concentration of DOPAC in the tissues. The 
reasons for these trends is not clear, but may be related to the selectively serotonergic 
toxicity of MDMA: MDMA causes damage to serotonergic fibers, decreasing serotonin and 
5-HIAA concentrations, but not to dopaminergic fibers, allowing increased release of DA 
and a subsequent increase in DOPAC concentration. 
The treatment regimen followed in this experiment was dictated by dosages 
employed in other studies (2,3,  4, 14, 20,26, 3 1, 32, 33, 34, 38,44). MDMA was 
administered in four doses in order to deliver a sufficient amount of the drug to induce 
toxicity while not overtly harming the animals. The amount of GM 1 administered (40 
mg/kg) reflected dosages used in other studies (10, 19). Alteration of the treatment 
regimen could have an appreciable effect on the results of the study. Although insignificant 
trends were observed a change in the treatment regimen (such as increasing the amount of 
GM 1 administered) may produce significant results in future trials. 
CONCLUSION 
The behavioral data suggests that animals recover more quickly from the behavioral 
effects of MDMA when given a collateral administration of GM 1. The biochemical data 
(although, admittedly, not as conclusive as the behavioral data) shows bends indicative of 
an enhanced rate of recovery from MDMA-induced toxicity in those animals that received 
collateral treatment with GM 1. Due to the nature of our results, it would seem safe to 
conclude that co-administration of GM 1 has an effect on the behavior of animals also 
treated with MDMA. However, a biochemical explanation as to the nature of that effect is 
still unclear. The results of this experiment indicate that further work is merited. 
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Appendix I 
Behavioral Activity 
Day 5 
Table A l .  Mean +- standard deviation for each hour of the 
24-hour period of the day 5 behavior activity study 
DAY 5 
TIME 
53:OO 
14:OO 
1 5:OO 
1 6:OO 
1 7:OO 
18:OO 
1 9:OO 
20:OO 
21:OO 
22:OO 
23:OO 
0:OO 
1:OO 
2: 00 
3:OO 
4:OO 
5: 00 
6:OO 
7: 00 
8:OO 
9:OO 
1 0:OO 
1 1:OO 
12:OO 
MDMA 
514.2 + 149.8 
531.8 f 225.2 
445.8 f 2 18.9 
167 + 171.9 
239.8 It 251.8 
325.6 k 443.2 
172.2 f 82.8 
201.8 f 106.9 
237.2 f 287.9 
118.2 f 6.1 
266.2 f 284.0 
50.6 f 22.1 
180.4 f 158.5 
296.4 4 355.5 
103.6 4 147.6 
162.8 4 147.0 
236.4 +. 244.0 
122 4 177.1 
254 +. 242.9 
252 2 188.8 
1 18.2 k 126.7 
244.8 + 312.5 
MDMA + GM1 
284.4 = 1 18.2 
200 f 180.6 
103.8 t 39.4 
86.8 t 47.9 
70 = 14.5 
74.6 r 65.4 
105.2 f 76.6 
90.8 _i 55.7 
59 C 11.9 
94.6 C 101.8 
93.2 + 107.6 
79.4 f 90.9 
153.2 181.1 
72.6 r 17.7 
194.6 = 1 52.0 
57 = 55.5 
99.4 f 90.9 
44.8 r 46.2 . 
61 r 27.8 
1 19.4 = 1 80.9 
92 2 61.4 
118.8 2 136.1 
Control 
321.2 F 275.8 
141.8 + 253.1 
33.8 + 47.2 
15.8 F 15.7 
29.8 F 51.1 
24.8 f 38.5 
25.8 f23.8 
39.6 ,C 57.5 
12.6 2 17.5 
2.2 f 0.8 
4.2 f 4.5 
16.4 k 22.6 
12.8 f 10.8 
55 f 90.6 
30.8 k 36.8 
57.2 k 65.7 
27.4 F 34.4 
47.4 +, 55.4 
65.6 + 60.4 
121 + 209.5 
39.6 +_ 39.3 
33 F 24.9 
65.6 1 8 2 . 2  
120.8 1: 241.3 
190.4 t 179.9 / 297.6 z 308.9 
129.4 2 101.9 110 101.7 
1 
GM1 
588.6 k 339.5 
357.2 f 277.3 
347.2 2 315.2 
225.4 f 241.0 
. 150.6k107.4 
229.2 f 151.6 
157 f 190.1 
100.8 rt: 80.4 
151.4 +. 152.8 
109.6 ,C 58.1 
199.8 5 112.5 
153.2 f 118.5 
156.4 + 154.9 
305.8 k 226.5 
57.8 k 48.8 
71.6 k 52.0 
68.4 -c 37.7 
141 +_ 177.7 
173.6 F 177.0 
184.8 k 171.5 
43  +_ 44.6 
33.6 k 20.1 
155.6 k 148.0 
31.6 t 18.5 
Appendix 11 
Behavioral Activity 
Day 1 2  
Table A2. Mean +- standard deviation for each hour of the 
24-hour period of the day 1 2  behavior activity study 
1 Day 12 
T~rne 
13:OO 
14:OO 
15:OO 
16:OO 
17:OO 
18:OO 
19:OO 
20:OO 
21:OO 
22:OO 
23:OO 
0:OO 
1:00 
2:OO 
3:OO 
4:OO 
5: 00 
6:OO 
7:OO 
8:OO 
9:OO 
1O:OO 
11.00 
12 00 
Control 
1040.2 576.6 
663.2 + 462.5 
532 r 511.9 
220.2 + 198.5 
146.4 + 63.5 
217.2 2 81.8 
203.4 i 254.3 
306.4 t 295.6 
21 0.8 + 152.4 
139.6 ;f 124.6 
147.2 2 261.9 
102.2+ 104 
140.8 k 83.9 
113.8 ? 98.2 
166.8 i 155.5 
237.2 = 458.8 
57.2 t 44.7 
19.4 c 1 7 7  
183.4 rt 245.1 
128 5 168.5 
116.4 c 125.8 
75.8 c 8.9 
1 1 5 6  t 1552 
173 6 = 1 3 4  6 
GM1 
1452.4 t 698.4 
1083.6 + 483.3 
823 +, 337.6 
395.4 +_ 485.4 
378  +' 243.4 
112 + 63.4 
178 2 114.5- 
266.6 + 255.5 
122.4 k 61.9 
75.2 + 74.8 
141.6 * 111.5 
113.4 t 46.4 
80.6 2 43.3 
104.2 + 87.6 
50.6 2 13.6 
67.6 i 39.8 
120.6 t 84.4 
11 3.6 2 90.2 
53.2 t 37.5 
72.4 2 49.7 
152.4 r 135.7 
263.2 r 382.0 
109 +_ 94 1 
1 3 4  4 5 149 7 
MDUA 
271.6 + 331.3 
162.6 2 68.2 
1 5 0  5 53.2 
137.8 2 65.5 
179.4 112.8 
21 6.2 a 178.7 
395.4 + 352.7 
246.6 + 289.2 
186.6 + 75.2 
119.2 k 78.5 
231.4 + 195.3 
188.6 r 139.4 
171.6 + 149.9 
149 k 90.9 
289.6 t 291.5 
179.6 f 158.5 
45.6 + 44.6 
58.2 + 43.2 
61.6 t 750  
57 4 t 64.8 
5 5 2  5 51.0 
28.8 2 199 
1 4 6  i_ 1 3 1  
39 8 1 5 1  9 
MDM4 + GM1 
1004.4 5 342.3 
874 5 469.2 
903.2 + 713.8 
601.2 t 196.3 
212.6 = 136.2 
227.4 2 130.7 
150.6 r 178.5 
208.8 r 102.8 
140.8 r 164.1 
93 + 48.2 
46 2 12.8 
176.8 5 104.1 
124.2 5 93.0 
268.4 + 287.8 
102.8 i 25.6 
108.2 r 68.6 
190.8 2 182.5 
248 + 130.6 
276.8 r 268.1 
233.4 i 156.3 
78.2 + 38.9 
214.8 .r 1077 
287 r 146.2 
2 4 4 2  = 1483 
